PRA-216 COPD Safety and Biomarker Study

Starting soon · Phase 2 · Has a placebo group

Conditions studied: Chronic Obstructive Pulmonary Disease (COPD)

In brief

This study will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to placebo in patients with chronic obstructive pulmonary disease (COPD).

Key facts

Study ID

NCT07730281

Run by

Prana Therapies Inc

People needed

40

Starts

2026-08-01

Expected to finish

2027-09-01

Last updated by the study team

2026-07-28

Who can join

Age: 40 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 40-80
• Willing and able to attend all study visits, comply with study requirements.
• Able and willing to provide written informed consent
• Documented COPD diagnosis prior for at least 12 months prior to screening.
• Currently receiving maintenance COPD medications at a stable dose for at least 2 months prior to visit 1

You may not qualify if…

• Evidence of clinically significant pulmonary condition or disease other than COPD
• Any physical or psychological condition that prohibits study completion
• Known history of illicit drug use or drug abuse, harmful alcohol use (at the Investigator's discretion), alcoholism within 12 months prior to the first dose of study agent
• History of severe allergic reactions or hypersensitivity
• Receipt of immunosuppressant therapies for asthma within 3 months of screening
• Major surgery occurring within 8 weeks months prior to first dose of investigational product.
• Use of any marketed or investigational monoclonal or polyclonal antibody therapy within 4 months or 5 half-lives prior to visit 1.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.